Amgen and KineMed Join Forces to Track Down Pathogenic Proteins

The “Disease Pathway Experts” at KineMed Inc. have teamed up with the drug development experts at Amgen in order to learn more about the stability and regulation of different proteins in neurodegenerative diseases like ALS. Using KineMed’s specialized mass spectrometry technology called the Dynamic Proteomics Platform, the two groups are teaming up to track the synthesis and breakdown rates of proteins that can become misfolded and accumulate in the brains of people with neurodegenerative diseases. By understanding the dynamics of misfolded proteins through this collaboration, the companies hope to develop diagnostic tests and drugs to potentially slow the spread of these diseases (let’s hope they are interested in looking at ALS-linked proteins TDP-43 and SOD1).

For more on the partnership and research plans, click here.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail